Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04111172 · ClinicalTrials.gov registry record · Phase 2
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
A Phase 2 study of Malignant Solid Neoplasm and Pancreatic Ductal Adenocarcinoma, sponsored by Thomas Jefferson University.
- Active
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT04111172 is a Phase 2 study of Malignant Solid Neoplasm and Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Thomas Jefferson University. The registered enrollment target is 48 participants, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04111172, a Phase 2 study of Malignant Solid Neoplasm and Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Thomas Jefferson University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase IIA trial investigates the side effects of Ad5.F35-hGCC-PADRE vaccine and to see how well it works in treating patients with gastrointestinal adenocarcinoma. Ad5.F35-hGCC-PADRE vaccine may help to train the patient's own immune system to identify and kill tumor cells and prevent it from coming back.
Conditions Studied
Interventions
- BIOLOGICAL Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
Study Locations (1)
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-11-10 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04111172
The ClinicalTrials.gov registry entry for NCT04111172 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (96% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE is the first listed.
NCT04111172 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04111172 about?
NCT04111172 is a clinical study titled "A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma". This phase IIA trial investigates the side effects of Ad5.F35-hGCC-PADRE vaccine and to see how well it works in treating patients with gastrointestinal adenocarcinoma. Ad5.F35-hGCC-PADRE vaccine may help to train the patient's own immune system to identify and kill tumor cells and prevent it from c...
What is the current status of trial NCT04111172?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-11-10. Estimated completion is 2027-03-01.
What conditions does trial NCT04111172 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Clinical Stage III Gastric Cancer AJCC v8.
What interventions are being tested in trial NCT04111172?
The interventions under investigation include: Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE (BIOLOGICAL).
Who is sponsoring clinical trial NCT04111172?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04111172 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
RECRUITING · Phase 2
-
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · Phase 2
-
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
RECRUITING · Phase 2
-
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
RECRUITING · Phase 2
-
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
RECRUITING · Phase 2
Explore more on PlainTrial
Malignant Solid Neoplasm
All registered trials for this condition
Pancreatic Ductal Adenocarcinoma
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.